Hemani Industries Limited Tackling Regulations Through Diversification
16 June 2022 Hemani Industries Limited (HIL) opened its first manufacturing site in Gujarat, India in 1992 and has since expanded to four sites serving customers in more than 55 countries. The company’s diversification plan is used to navigate a world putting more restraints on active ingredients (AIs). HIL shared with AgriBusiness Global its plan for expansion to accommodate these agchem industry regulations.
ABG: How has your company changed in what its offering?
HIL: When we started, the company produced only pyrethroids. In 2011, we started producing AIs and offered our global customer base technical AIs, that include cypermethrin, aphacypermethrin, permethrin, deltamethrin, lambda cyhalothrin, zeta-cypermethrin, bifenthrin, prosulfocarb, metamitron, metribuzin, dicamba, and mesotrione.
Apart from the technical AIs, we also produce intermediates like MPBD, CMAC, bromobenzene, 3 CPC, and 2,5 DCA. Going forward, we are also planning to build intermediate facilities for benzyldehyde, which will help us make our pyrethroid chemistry more competitive.
ABG: What are two challenges you see affecting the ag chemical industry in the next year?
HIL: Supply chain and logistics disruption due to COVID-19 and the geopolitical situation in Ukraine. There is enormous volatility in raw material pricing due to the imbalance between demand and supply. In addition, we must navigate increasingly more restrictive regulatory requirements.
ABG: How is your company helping with these issues?
HIL: Backward integration helps us reduce dependency on imports and third-party purchases. We employ continuous process innovation to keep our products competitive and get the best possible output with the most efficient input utilization. In addition, we closely watch global trends and continually communicate with our suppliers and other industry experts. This helps us reduce the impact of volatility in prices of raw material on our final price offerings to our clients. We are also able to reduce delivery times for our clients through our subsidiaries in Korea and Australia, and our warehousing facilities in Rotterdam (the Netherlands), Riga (Latvia), and in the future in Istanbul (Turkey).
ABG: Do you have any new products coming out?
HIL: We are working on a number of new offerings including: Sulfentrazone, mesotrione, acetamiprid, profenofos, propiconazole, clomazone, and chlorantraniliprole.
ABG: How else are you dealing with regulations?
HIL: We have an excellent regulatory team with experts from a variety of fields including agriculture, chemistry, and zoology who are supported by reputable consultants from countries around the world. All of our data is generated through respected GLP laboratories like Advinus, RCC, IIBAT, and QSAR Analytics.
We are ready to provide GLP dossiers ― as per global requirements ― for all our core products.
Get The Newsletter Today!
